National Advertising Review Board Recommends Genexa Discontinue or Modify Pediatrician Preference and Ingredient Claims for “Kids’ Pain & Fever” Medicine
New York, NY – February 14, 2023 – A panel of the National Advertising Review Board (NARB), the appellate advertising law body of BBB National Programs, recommended that Genexa Inc. discontinue certain pediatrician preference claims and ingredient claims for its acetaminophen-based children’s analgesic sold over the counter as “Kids’ Pain & Fever.”
The advertising at issue had been challenged before the National Advertising Division (NAD) by Johnson & Johnson Consumer, Inc., McNeil Healthcare Division. Following NAD’s decision (Case No. 7108), Genexa appealed NAD’s findings and recommendations.
While the active ingredient in both parties’ medications (acetaminophen) is the same, Genexa has disseminated superiority claims for Kids’ Pain & Fever compared to competing brands based on asserted advantages attributable to its product’s inactive ingredients.
Pediatrician Preference Claims
Johnson & Johnson challenged the following pediatrician preference claims:
- “Pediatricians prefer Genexa’s Kids’ Pain & Fever over Children’s Tylenol Pain + Fever liquid products for their own children based upon comparing the ingredients”; and
- “The doctors have spoken.”
In agreement with NAD, the NARB panel concluded that one message conveyed by the “pediatricians prefer” claim is that pediatricians prefer the Genexa product for use by their own children. Further, the NARB panel concluded that the “doctors have spoken” claim communicates to reasonable consumers that pediatricians prefer Genexa’s medication to competitive products on the market, including recommending the Genexa medicine in their practice.
Finding no support for either of these messages, the NARB panel recommended that the claims be discontinued or modified to make clear that the surveyed pediatricians expressed a preference only as to “ingredients,” and avoid stating or implying that pediatricians prefer or use the advertiser’s product over the challenger’s product in their practices or for their own children.
Ingredient Claims
In the underlying decision, NAD found that the challenged claims convey the message that there are inactive ingredients in competitors’ products, including Johnson & Johnson’s, that are dangerous and unsafe. NAD recommended that these claims be discontinued for lack of support.
The NARB panel affirmed NAD’s conclusions and recommendations concerning the challenged ingredient claims. Among the claims the panel recommended be discontinued was the claim “PARABENS is stuff you’ll find in ALL PURPOSE CLEANER. And, for some reason, in kids’ fever medicine.”
The NARB panel also recommended that the advertiser discontinue the “MADE WITH REAL INGREDIENTS” claim in the context presented in the now-discontinued challenged video advertisement and avoid conveying the message that competing products with different inactive ingredients are generally unsafe, harmful, or dangerous. The panel noted that nothing in its decision prevents the advertiser from highlighting the “real ingredients” in its product, provided, that the advertising does not otherwise convey the message that competing products contain inactive ingredients that are generally unsafe, harmful, or dangerous.
Genexa stated that it “is deeply troubled by the implications of NARB's decision on both Genexa and the industry more broadly, but Genexa will comply with NARB's recommendations.”
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive.
Contact: Abby Hills, Director of Communications, BBB National Programs
703-247-9330 / press@bbbnp.org
Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.
Latest Decisions
Following National Advertising Division Inquiry, Google Voluntarily Unlists Video Demonstrating Google Gemini Capabilities
New York, NY – September 12, 2024 – Google voluntarily unlisted a video demonstrating the capabilities of Google Gemini, its large language model artificial intelligence (AI) offering introduced in December 2023.
National Advertising Division Recommends Gruma Modify Sugar and Net Carbohydrate Label Claims
New York, NY – September 11, 2024 – In a challenge brought by competitor Olé, the National Advertising Division found certain “zero sugar” and “0G sugar” claims supported and recommended that Gruma Corporation, in connection with its tortilla product offerings, modify or discontinue other claims.
Direct Selling Self-Regulatory Council Recommends MONAT Discontinue Earnings Claims
McLean, VA – September 5, 2024 – The Direct Selling Self-Regulatory Council (DSSRC) recommended MONAT Global discontinue certain earnings claims made on the MONAT website and by salesforce members on Facebook, Twitter/X, Instagram, and YouTube.
National Advertising Division Refers HiSmile Teeth Whitening Product Claims to the Federal Trade Commission